What is Biosense?
BIOSENSE is at the forefront of personalized metabolic health, specializing in a clinically validated breath ketone monitor. This non-invasive device offers real-time biofeedback, enabling users to precisely track their fat burn journey. By analyzing deep lung air samples, BIOSENSE provides an alternative to painful finger-prick blood tests, making ketone monitoring more accessible and user-friendly. Endorsed by metabolic experts, the technology is designed for health-conscious individuals aiming to optimize ketosis during fasting, achieve specific metabolic goals, and enhance overall well-being.
How much funding has Biosense raised?
Biosense has raised a total of $2.2M across 1 funding round:
Angel/Seed
$2.2M
Angel/Seed (2020): $2.2M with participation from iSelect Funds
Key Investors in Biosense
iSelect Funds
iSelect Funds is an investment entity that has participated in the early-stage funding for Biosense. Their involvement suggests a focus on innovative health technology and metabolic solutions.
What's next for Biosense?
With the recent major strategic investment, Biosense is poised for accelerated growth and market penetration. The company's focus on a non-invasive, user-friendly approach to metabolic tracking positions it favorably within the burgeoning digital health and wellness industry. Future endeavors will likely involve scaling production, enhancing the device's capabilities through further research and development, and expanding its reach to a broader consumer base seeking data-driven insights into their health and fitness. This strategic backing signals strong confidence in Biosense's potential to become a leader in the personalized metabolic health monitoring space.
See full Biosense company page
